Clinical Trials Directory

Trials / Completed

CompletedNCT03195946

Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes

Interventional, Open-label, Multiple-dose Study to Investigate the Effects of Multiple Doses of Lu AF35700 on the Pharmacokinetics of Cytochrome P450 (CYP450) Substrates Dextromethorphan (CYP2D6), Caffeine (CYP1A2), Omeprazole (CYP2C19), and Midazolam (CYP3A4/5) in Healthy Young Adults

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
H. Lundbeck A/S · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This study will help determine which types of drugs that may interact with Lu AF35700

Conditions

Interventions

TypeNameDescription
DRUGLu AF35700tablets for oral use, 10 mg/day
DRUGMidazolamsyrup for oral use, 4mg/day
DRUGCocktail of CYP450 substratesCaffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day

Timeline

Start date
2017-06-16
Primary completion
2018-01-03
Completion
2018-01-03
First posted
2017-06-22
Last updated
2018-01-08

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03195946. Inclusion in this directory is not an endorsement.